glp 1 mash approval GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT FOR SERIOUS LIVER DISEASE Semaglutide, a medication already known for its role in weight management, is now the first GLP-1 therapy approved to treat (Metabolic Dysfunction–Associated Novo Nordisk's Wegovy gets accelerated

With the right strategies in place, telehealth can support safe and effective GLP-1 therapy initiation

Defined as less than 10% total body weight loss by month 6, or weight-loss plateau with more than 10% remaining to goal

Nonetheless, established neurodegenerative diseases have a limited response, underscoring the need of prevention rather than therapy

M.KoroC

Patients typically experience increased appetite within days to weeks, as ghrelin (hunger hormone) rises and glucagon-like peptide-1 signaling returns to pre-treatment levels

These effects often lead to substantial weight loss, but roughly 25-40% of that weight loss can come from lean muscle tissue, especially without resistance training or nutritional support